Heatwurx (NASDAQ:PCSA) Posts Earnings Results, Misses Estimates By $0.19 EPS

Heatwurx (NASDAQ:PCSA) posted its quarterly earnings data on Friday. The company reported ($1.19) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.19), Zacks reports.

Heatwurx Trading Down 2.8%

Shares of NASDAQ:PCSA opened at $2.43 on Friday. The firm has a market capitalization of $6.73 million, a PE ratio of -0.26 and a beta of 0.99. Heatwurx has a 1-year low of $1.67 and a 1-year high of $14.24. The business’s 50 day moving average is $2.23 and its 200-day moving average is $2.50.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Heatwurx in a report on Friday, July 17th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $25.00.

About Heatwurx

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.